Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa

Thrombosis Research

Volumn 122, Issue SUPPL. 4, 2008, Pages

  Schulte, Stefan ^a  

^a CSL BEHRING GMBH   (Germany)

Author keywords

Albumin fusion protein; Albumin fusion technology; AUC; cDNA; CFT; Coagulation factor; Factor VII; Fc; FVIIa; FVIII; Half life extension; Recombinant factor VIIa; rFVII; rFVIIa; ROTEM ; rVII FP; rVIIa FP; SDS PAGE; wt

Indexed keywords

ALBUMIN; BLOOD CLOTTING FACTOR 7A; GLYCINE; HYBRID PROTEIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT BLOOD CLOTTING FACTOR 7A FUSION PROTEIN; SERINE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; BLEEDING; CARBOXY TERMINAL SEQUENCE; CIRCULATION; DRUG ACTIVITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; HEMOPHILIA A; HEMOSTASIS; HUMAN; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

ALBUMINS; ANIMALS; FACTOR VIIA; HALF-LIFE; HUMANS; RATS; RECOMBINANT FUSION PROTEINS; RECOMBINANT PROTEINS;

EID: 53449102958     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(08)70029-X     Document Type: Article

References (10)

1. World Federation of Hemophilia. Guidelines for the management of hemophilia, 2005. Montréal: World Federation of Hemophilia. Available from: www.wfh.org/2/docs/Publications/Diagnosis_and_Treatment/Guidelines_Mng_Hemophilia.pdf [accessed June 22, 2008].
2. Hedner U. Mechanism of action of recombinant activated factor VII: an update. Semin Hematol 43 1 Suppl 1 (2006) S105-S107
3. Novo N. NovoSeven® summary of product characteristics. Available from: www.emea.europa.eu/humandocs/PDFs/EPAR/Novoseven/H-074-PI-en.pdf [accessed June 23, 2008].
4. Chuang V.T., Kragh-Hansen U., and Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 19 (2002) 569-577
5. Dumont J.A., Low S.C., Peters R.T., and Bitonti A.J. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs 20 (2006) 151-160
6. Balan V., Nelson D.R., Sulkowski M.S., Everson G.T., Lambiase L.R., Wiesner R.H., et al. A phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferonalpha-based therapy. Antivir Ther 11 (2006) 35-45
7. Duttaroy A., Kanakaraj P., Osborn B.L., Schneider H., Pickeral O.K., Chen C., et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes 54 (2005) 251-258
8. Breton J., Pezzi N., Molinari A., Bonomini L., Lansen J., Gonzalez De Buitrago G., et al. Prolonged half-life in the circulation of a chemical conjugate between a prourokinase derivative and human serum albumin. Eur J Biochem 231 (1995) 563-569
9. Sheffield W.P., Smith I.J., Syed S., and Bhakta V. Prolonged in vivo anticoagulant activity of a hirudin-albumin fusion protein secreted from Pichia pastoris. Blood Coagul Fibrinolysis 12 (2001) 433-443
10. Weimer T., Wormsb̈acher W., Kronthaler U., Lang W., Liebing U., and Schulte S. Prolonged in-vivo half-life of factor VIIa by fusion to albumin. Thromb Haemost 99 (2008) 659-667